Skip to main content
Premium Trial:

Request an Annual Quote

Agilent and Dharmacon To Combine Microarrays, RNAi

NEW YORK, June 24 - Agilent Technologies and Dharmacon have begun a collaboration to combine Agilent's microarrays and Dharmacon's RNA interference for a measure of gene silencing, the companies said today.

 

Under the agreement, Dharmacon researchers will use RNAi to silence genes and then measure the effects of silencing with Agilent microarrays, and analyze the effect of the RNAi on gene expression with Rosetta Resolver software.

 

This initial collaboration aims at optimizing the companies' methods for use of their technologies together in research.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.